Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation

Lédée, Nathalie; Vasseur, Claudine; Petitbarat, Marie; Chevrier, L.; Vezmar, Katia; Dray, Géraldine; Chenière, Sandra; Lobersztajn, Annina; Vitoux, Dominique; Cassuto, Nino Guy; Chaouat, Gérard

doi:10.1016/j.jri.2018.09.050

Cited by 38 publications

(41 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous authors reported that intravenous slow perfusion of diluted Intralipid R could be useful to control the hyper-activation of circulating NK cells and to regulate a Th-1 predominant cytokine balance (43,44). We personally observed and reported a local reduction of Th-1 cytokines as well as a better control of uNK cells recruitment after intravenous perfusion of intralipids (45).…”

Section: Immunotherapymentioning

confidence: 76%

Endometrial Immune Profiling: A Method to Design Personalized Care in Assisted Reproductive Medicine

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Immunotherapymentioning

confidence: 76%

Endometrial Immune Profiling: A Method to Design Personalized Care in Assisted Reproductive Medicine

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, the authors mentioned that women with abnormal NK cell activity were included in the study, but the data for NK cell activity were not shown. Martini et al (2018) did not observe any increase in the live birth rate in a retrospective intralipid cohort (n = 127) study compared with the historical control cohort (n = 20) data 5‐7,12,19 …”

Section: Lipid Emulsion Therapy In Rpl and Rifmentioning

confidence: 95%

Lipid emulsion therapy in women with recurrent pregnancy loss and repeated implantation failure: The role of abnormal natural killer cell activity

Canella

Barini

Carvalho

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Altered immune and/or inflammatory response plays an important role in cases of recurrent pregnancy loss (RPL) and repeated implantation failure (RIF). Exacerbation of the maternal immune response through increased NK cell activity and inflammatory cytokines can cause embryo rejection leading to abortion or embryo implantation failure. Immunosuppressors or immunomodulators can help or prevent this condition. Currently, lipid emulsion therapy (LET) has emerged as a treatment for RPL and RIF in women with abnormal NK cell activity, by decreasing the exacerbated immune response of the maternal uterus and providing a more receptive environment for the embryo. However, the mechanisms by which the intralipid acts to reduce NK cell activity are still unclear. In this review, we focus on the studies that conducted LET to treat patients with RPL and RIF with abnormal NK cell activity. We find that although some authors recommend LET as an effective intervention, more studies are necessary to confirm its effectiveness in restoring NK cell activity to normal levels and to comprehend the underlying mechanisms of the lipids action in ameliorating the maternal environment and improving the pregnancy rate.

show abstract

“…Patients with the essential fatty acid deficiency have a susceptibility to infection (Fell et al, 2015), and intralipid® infusion is indicated for these patients. In women with RFI, Intralipid® infusion (low dose and monthly administration) has been reported to suppress immune properties of circulating NK cells and decrease the hyper-activation of uterine NK cells through the regulation of NK cell recruitment and the downregulation of endometrial IL-18 and IL-15 (Lédée et al, 2018b). There is no evidence that Intralipid® infusion increases infection susceptibility.…”

Section: Intralipid Treatmentmentioning

confidence: 99%

COVID-19 and immunomodulation treatment for women with reproductive failures

Kwak‐Kim

Ota

Sung

et al. 2020

Journal of Reproductive Immunology

Self Cite

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation

Cited by 38 publications

References 32 publications

Endometrial Immune Profiling: A Method to Design Personalized Care in Assisted Reproductive Medicine

Endometrial Immune Profiling: A Method to Design Personalized Care in Assisted Reproductive Medicine

Lipid emulsion therapy in women with recurrent pregnancy loss and repeated implantation failure: The role of abnormal natural killer cell activity

COVID-19 and immunomodulation treatment for women with reproductive failures

Contact Info

Product

Resources

About